

# Pedro Romero

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7031521/pedro-romero-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

310 papers	22,108 citations	78 h-index	138 g-index
322 ext. papers	25,121 ext. citations	9.2 avg, IF	6.43 L-index

#	Paper	IF	Citations
310	Lighting up the tumor fire with low-dose irradiation.. <i>Trends in Immunology</i> , <b>2022</b> ,	14.4	1
309	The Era of Cytotoxic CD4 T Cells.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 867189	8.4	2
308	Enforced PGC-1 $\beta$ expression promotes CD8 T cell fitness, memory formation and antitumor immunity. <i>Cellular and Molecular Immunology</i> , <b>2021</b> , 18, 1761-1771	15.4	24
307	Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	25
306	Fibroblast Activation Protein $\beta$ -Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4036-4053	12.9	6
305	CD40 Agonist Targeted to Fibroblast Activation Protein $\beta$ Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4054-4065	12.9	6
304	Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	4
303	Metabolic reprogramming of terminally exhausted CD8 T cells by IL-10 enhances anti-tumor immunity. <i>Nature Immunology</i> , <b>2021</b> , 22, 746-756	19.1	40
302	PPAR $\gamma$ drives IL-33-dependent ILC2 pro-tumoral functions. <i>Nature Communications</i> , <b>2021</b> , 12, 2538	17.4	7
301	CD73 expression in normal, hyperplastic, and neoplastic thyroid: a systematic evaluation revealing CD73 overexpression as a feature of papillary carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 479, 209-214	5.1	1
300	Gain of HIF1 Activity and Loss of miRNA Promote Breast Cancer Metastasis to the Brain via the PDGF/PDGFR Axis. <i>Cancer Research</i> , <b>2021</b> , 81, 594-605	10.1	7
299	Human primed ILCpS support endothelial activation through NF- $\kappa$ B signaling. <i>ELife</i> , <b>2021</b> , 10,	8.9	1
298	Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	29
297	An Immunomodulatory Gallotannin-Rich Fraction From Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 584959	8.4	5
296	An optimized antigen-protein fusion. <i>Nature Biomedical Engineering</i> , <b>2020</b> , 4, 583-584	19	2
295	Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 340	8.4	12
294	Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 173-182	7.5	13

293	Immunosuppressive Mediators Impair Proinflammatory Innate Lymphoid Cell Function in Human Malignant Melanoma. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 556-564	12.5	12
292	Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells. <i>Journal of Leukocyte Biology</i> , <b>2020</b> , 108, 723-737	6.5	13
291	Recombinant fusion proteins for targeting dendritic cell subsets in therapeutic cancer vaccine. <i>Methods in Enzymology</i> , <b>2020</b> , 632, 521-543	1.7	1
290	Generation of affinity ranged antigen-expressing tumor cell lines. <i>Methods in Enzymology</i> , <b>2020</b> , 632, 503-519	1.7	
289	miR-155 Overexpression in OT-1 CD8 T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 16, 111-123	6.4	7
288	Assessment of memory formation by metabolically engineered antigen-specific CD8 T cells. <i>Methods in Enzymology</i> , <b>2020</b> , 631, 77-90	1.7	
287	Detecting and analyzing murine innate lymphoid cells. <i>Methods in Enzymology</i> , <b>2020</b> , 631, 329-342	1.7	1
286	Metabolic and epigenetic regulation of T-cell exhaustion. <i>Nature Metabolism</i> , <b>2020</b> , 2, 1001-1012	14.6	47
285	Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2121	8.4	19
284	Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. <i>Nature Immunology</i> , <b>2019</b> , 20, 206-217	19.1	31
283	F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1859-1868	8.8	35
282	Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 925	8.4	159
281	High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4320-4331	12.9	10
280	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells <b>2019</b> , 7, 109		65
279	MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 1013-1024	12.5	18
278	Siglec-9 Regulates an Effector Memory CD8 T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 707-718	12.5	56
277	Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 425-441	19.4	223
276	The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance. <i>Cell Stem Cell</i> , <b>2019</b> , 24, 405-418.e7	18	81

275	CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival. <i>Cancer Research</i> , <b>2019</b> , 79, 5245-5259	10.1	19
274	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8 T cells <b>2019</b> , 7, 257		54
273	Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 294	8.4	13
272	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. <i>Blood Advances</i> , <b>2019</b> , 3, 3674-3687	7.8	23
271	CD73 expression in normal and pathological human hepatobiliopancreatic tissues. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 467-478	7.4	20
270	Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic T Cell Death and May Contribute to Type 1 Diabetes Development. <i>Cell Metabolism</i> , <b>2019</b> , 29, 348-361.e6	24.6	119
269	Mitochondria-Endoplasmic Reticulum Contact Sites Function as Immunometabolic Hubs that Orchestrate the Rapid Recall Response of Memory CD8 T Cells. <i>Immunity</i> , <b>2018</b> , 48, 542-555.e6	32.3	75
268	Sensitive and frequent identification of high avidity neo-epitope-specific CD8 T cells in immunotherapy-naïve ovarian cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 1092	17.4	82
267	Autocrine Adenosine Regulates Tumor Polyfunctional CD73CD4 Effector T Cells Devoid of Immune Checkpoints. <i>Cancer Research</i> , <b>2018</b> , 78, 3604-3618	10.1	40
266	Rationale for immunological approaches to breast cancer therapy. <i>Breast</i> , <b>2018</b> , 37, 187-195	3.6	14
265	CART cells are prone to Fas- and DR5-mediated cell death <b>2018</b> , 6, 71		33
264	PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells. <i>Journal of Immunology</i> , <b>2018</b> , 201, 792-803	5.3	19
263	CD73 expression and clinical significance in human metastatic melanoma. <i>Oncotarget</i> , <b>2018</b> , 9, 26659-26669	5.9	31
262	Metabolic Control of CD8 T Cell Fate Decisions and Antitumor Immunity. <i>Trends in Molecular Medicine</i> , <b>2018</b> , 24, 30-48	11.5	104
261	Tumor Resident Memory T Cells: New Players in Immune Surveillance and Therapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2076	8.4	43
260	Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPAR $\alpha$ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth. <i>Cancer Research</i> , <b>2018</b> , 78, 6447-6461	10.1	12
259	Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor Growth. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 356	5.3	17
258	Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8 T cells. <i>OncImmunology</i> , <b>2017</b> , 6, e1318234	7.2	7

257	Curtailed T-cell activation curbs effector differentiation and generates CD8 T cells with a naturally-occurring memory stem cell phenotype. <i>European Journal of Immunology</i> , <b>2017</b> , 47, 1468-1476	6.1	16
256	The Vast Universe of T Cell Diversity: Subsets of Memory Cells and Their Differentiation. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1514, 1-17	1.4	3
255	Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 717-725	12.9	19
254	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1918	8.4	55
253	TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	24
252	CD8 T Lymphocytes in Antitumor Immunity <b>2016</b> , 434-440		
251	The Human Vaccines Project: A roadmap for cancer vaccine development. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 334ps9	17.5	115
250	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge-Napoli, December 5th 2015 <b>2016</b> , 4,		78
249	Epitope located N-glycans impair the MHC-I epitope generation and presentation. <i>Electrophoresis</i> , <b>2016</b> , 37, 1448-60	3.6	9
248	Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model. <i>Cell Death and Disease</i> , <b>2016</b> , 7, e2243	9.8	28
247	Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner. <i>Cell Reports</i> , <b>2016</b> , 14, 1206-1217	10.6	80
246	Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells. <i>EBioMedicine</i> , <b>2016</b> , 4, 50-61	8.8	65
245	An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. <i>Oncotarget</i> , <b>2016</b> , 7, 21199-221	3.3	27
244	Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients. <i>Frontiers in Immunology</i> , <b>2016</b> , 7, 573	8.4	50
243	Piezoresistive Membrane Surface Stress Sensors for Characterization of Breath Samples of Head and Neck Cancer Patients. <i>Sensors</i> , <b>2016</b> , 16,	3.8	10
242	NLR5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. <i>Nature Communications</i> , <b>2016</b> , 7, 10554	17.4	35
241	IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner. <i>Journal of Immunology</i> , <b>2016</b> , 197, 85-96	5.3	20
240	Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8 and CD4 T-cell responses with multiple specificities including a novel DR7-restricted epitope. <i>OncolImmunology</i> , <b>2016</b> , 5, e1216290	7.2	39

239	Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 6140-5	11.5	380
238	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors <b>2015</b> , 3, 15		47
237	Local immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. <i>Onc Immunology</i> , <b>2015</b> , 4, e1016697	7.2	10
236	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. <i>Onc Immunology</i> , <b>2015</b> , 4, e1029702	7.2	10
235	JITC launches a new section: commentary and editorials <b>2015</b> , 3, 28		
234	Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer <b>2015</b> , 3, 49		
233	Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>Onc Immunology</i> , <b>2015</b> , 4, e998538	7.2	101
232	CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis. <i>Haematologica</i> , <b>2015</b> , 100, e257-60	6.6	53
231	The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death. <i>Blood</i> , <b>2015</b> , 126, 1019-1023		
230	T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. <i>Nature Reviews Immunology</i> , <b>2014</b> , 14, 768-74	36.5	191
229	Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 436-47	12.5	147
228	A microRNA profile of human CD8(+) regulatory T cells and characterization of the effects of microRNAs on Treg cell-associated genes. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 218	8.5	27
227	MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 97	8.5	58
226	Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder. <i>Journal of Urology</i> , <b>2014</b> , 191, 814-22	2.5	12
225	Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 1810-20	15.9	224
224	Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans. <i>European Journal of Immunology</i> , <b>2014</b> , 44, 2567-70	6.1	9
223	Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 1199-211	7.4	20
222	iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine <b>2014</b> , 2, 39		11

221	Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function. <i>Journal of Immunology</i> , <b>2014</b> , 193, 1759-65	5.3	55
220	The role of the reporting framework MIATA within current efforts to advance immune monitoring. <i>Journal of Immunological Methods</i> , <b>2014</b> , 409, 6-8	2.5	3
219	CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. <i>Cancer Immunology, Immunotherapy</i> , <b>2013</b> , 62, 747-60	7.4	24
218	Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. <i>Cancer Research</i> , <b>2013</b> , 73, 6597-608	10.1	68
217	Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , <b>2013</b> , 132, E85-93	7.5	69
216	MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. <i>Immunity</i> , <b>2013</b> , 38, 742-53	32.3	204
215	Vaccination route matters for mucosal tumors. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 172fs4	17.5	15
214	Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships. <i>PLoS ONE</i> , <b>2013</b> , 8, e65590	3.7	3
213	Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. <i>Clinical and Developmental Immunology</i> , <b>2013</b> , 2013, 875343		7
212	SHP-1 phosphatase activity counteracts increased T cell receptor affinity. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 1044-56	15.9	82
211	Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e78686	3.7	12
210	Structured reporting of T cell assay results. <i>Cancer Immunity</i> , <b>2013</b> , 13, 13		5
209	Peptide and Protein-Based Cancer Vaccines <b>2013</b> , 111-146		1
208	Virus-like particles induce robust human T-helper cell responses. <i>European Journal of Immunology</i> , <b>2012</b> , 42, 330-40	6.1	58
207	Saponins from the Spanish saffron <i>Crocus sativus</i> are efficient adjuvants for protein-based vaccines. <i>Vaccine</i> , <b>2012</b> , 30, 388-97	4.1	18
206	MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 9910-9922	5.4	62
205	NLR5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells. <i>Journal of Immunology</i> , <b>2012</b> , 188, 3820-8	5.3	97
204	Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine <b>2012</b> , 417-440		1



203 Melanoma Vaccines **2012**, 207-232

202	What is the influence of vaccination's routes on the regression of tumors located at mucosal sites?. <i>Oncolimmunology</i> , <b>2012</b> , 1, 242-243	7.2	6
201	Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. <i>Cancer Research</i> , <b>2012</b> , 72, 4629-41	10.1	141
200	Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 23068-78	5.4	86
199	Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytotoxicity directly ex vivo. <i>Oncolimmunology</i> , <b>2012</b> , 1, 467-530	7.2	12
198	Harmonization of immune biomarker assays for clinical studies. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 108ps44	17.5	81
197	Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 2625-34	7.5	57
196	MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 23-35	7.4	22
195	A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. <i>Journal of Translational Medicine</i> , <b>2011</b> , 9, 108	8.5	24
194	Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. <i>Journal of Translational Medicine</i> , <b>2011</b> , 9, 44	8.5	58
193	Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. <i>European Journal of Immunology</i> , <b>2011</b> , 41, 2217-28	6.1	59
192	Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. <i>International Journal of Cancer</i> , <b>2011</b> , 129, 762-72	7.5	26
191	Type I interferon inhibits interleukin-1 production and inflammasome activation. <i>Immunity</i> , <b>2011</b> , 34, 213-23	32.3	651
190	TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. <i>Cancer Research</i> , <b>2011</b> , 71, 1607-14	10.1	87
189	Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. <i>Cancer Research</i> , <b>2011</b> , 71, 5976-86	10.1	179
188	Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 15318-23	11.5	17
187	Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 2350-60	15.9	549
186	Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 20481-91	5.4	21



185	Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity. <i>MBio</i> , <b>2010</b> , 1,	7.8	32
184	Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. <i>Journal of Immunology</i> , <b>2010</b> , 184, 4936-46	5.3	148
183	Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. <i>Seminars in Immunology</i> , <b>2010</b> , 22, 144-54	10.7	37
182	Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. <i>Journal of Immunotherapy</i> , <b>2010</b> , 33, 723-34	5	16
181	Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. <i>Journal of Immunotherapy</i> , <b>2010</b> , 33, 848-58	5	111
180	Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells. <i>Blood</i> , <b>2010</b> , 115, 5154-63	2.2	42
179	Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. <i>International Journal of Cancer</i> , <b>2010</b> , 126, 2469-78	7.5	14
178	BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 157-67	15.9	219
177	Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses. <i>Methods in Molecular Biology</i> , <b>2010</b> , 626, 231-49	1.4	2
176	Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. <i>Cancer Research</i> , <b>2009</b> , 69, 8085-93	10.1	37
175	The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. <i>Journal of Immunology</i> , <b>2009</b> , 182, 3510-21	5.3	141
174	Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase. <i>Journal of Immunology</i> , <b>2009</b> , 182, 6718-26	5.3	18
173	Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. <i>Journal of Immunology</i> , <b>2009</b> , 182, 6328-41	5.3	46
172	Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. <i>Journal of Immunology</i> , <b>2009</b> , 183, 5397-406	5.3	41
171	Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. <i>Journal of Immunology</i> , <b>2009</b> , 182, 5140-51	5.3	84
170	Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. <i>Journal of Immunology</i> , <b>2009</b> , 183, 319-31	5.3	55
169	Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 649-55	7.5	25
168	Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. <i>European Journal of Immunology</i> , <b>2009</b> , 39, 1608-18	6.1	228

167	Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 1701-13	7.4	58
166	"MIATA"-minimal information about T cell assays. <i>Immunity</i> , <b>2009</b> , 31, 527-8	32.3	161
165	Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 2307-12	11.5	170
164	Toll-like receptor 3 is necessary for dsRNA adjuvant effects. <i>Vaccine</i> , <b>2009</b> , 27, 1841-7	4.1	16
163	Recent advances and hurdles in melanoma immunotherapy. <i>Pigment Cell and Melanoma Research</i> , <b>2009</b> , 22, 711-23	4.5	38
162	Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. <i>Journal of Immunotherapy</i> , <b>2009</b> , 32, 875-83	5	13
161	Lack of functionally active Melan-A(26-35)-specific T cells in the blood of HLA-A2+ vitiligo patients. <i>Journal of Investigative Dermatology</i> , <b>2008</b> , 128, 1977-80	4.3	6
160	Current state of vaccine therapies in non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2008</b> , 9 Suppl 1, S28-36	4.9	21
159	Tumour immunity: effector response to tumour and role of the microenvironment. <i>Lancet, The</i> , <b>2008</b> , 371, 771-83	40	415
158	Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. <i>Journal of Immunology</i> , <b>2008</b> , 180, 391-401	5.3	78
157	Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 3849-54	11.5	115
156	Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor. <i>International Immunology</i> , <b>2008</b> , 20, 1087-96	4.9	13
155	Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 15010-5	11.5	33
154	Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. <i>Molecular Therapy</i> , <b>2008</b> , 16, 985-94	11.7	38
153	Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 303-15	7.4	172
152	Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 1795-803	7.4	62
151	Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 2307-17		301
150	An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain. <i>Cancer Immunity</i> , <b>2008</b> , 8, 6		2

149	Toll-like receptors' two-edged sword: when immunity meets apoptosis. <i>European Journal of Immunology</i> , <b>2007</b> , 37, 3311-8	6.1	129
148	Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 839-47	7.4	26
147	Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 1795-805	7.4	9
146	Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 1979-91	7.4	18
145	Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages. <i>Journal of Immunology</i> , <b>2007</b> , 179, 7406-14	5.3	37
144	In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. <i>Journal of Immunology</i> , <b>2007</b> , 179, 2368-79	5.3	25
143	IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. <i>Journal of Immunology</i> , <b>2007</b> , 178, 3566-74	5.3	16
142	A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. <i>Journal of Immunology</i> , <b>2007</b> , 179, 7635-45	5.3	20
141	Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. <i>Journal of Immunology</i> , <b>2007</b> , 178, 4112-9	5.3	283
140	In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 12457-61	11.5	93
139	Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. <i>Blood</i> , <b>2007</b> , 110, 3564-72	7.2	87
138	Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. <i>Journal of Immunotherapy</i> , <b>2007</b> , 30, 533-43	5	18
137	Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. <i>Journal of Immunotherapy</i> , <b>2007</b> , 30, 240-50	5	25
136	Potential target antigens for immunotherapy in human pancreatic cancer. <i>Cancer Letters</i> , <b>2007</b> , 252, 290-8	9.9	24
135	Toll-like receptor 3 expressed by melanoma cells as a target for therapy?. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 4565-74	12.9	171
134	TLR3 deficiency in patients with herpes simplex encephalitis. <i>Science</i> , <b>2007</b> , 317, 1522-7	33.3	842
133	Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. <i>Journal of Immunological Methods</i> , <b>2006</b> , 309, 192-9	2.5	37
132	Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. <i>Journal of Immunological Methods</i> , <b>2006</b> , 310, 136-48	2.5	52

131	LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry. <i>Journal of Immunological Methods</i> , <b>2006</b> , 311, 31-46	2.5	26
130	Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. <i>European Journal of Immunology</i> , <b>2006</b> , 36, 1805-14	6.1	14
129	A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. <i>Journal of Immunology</i> , <b>2006</b> , 177, 1338-48	5.3	66
128	Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. <i>Cancer Research</i> , <b>2006</b> , 66, 1912-61	6.1	44
127	Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. <i>Journal of Immunology</i> , <b>2006</b> , 177, 8708-13	5.3	98
126	Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. <i>Journal of Immunology</i> , <b>2006</b> , 177, 6769-79	5.3	45
125	Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. <i>Journal of Immunology</i> , <b>2006</b> , 176, 2330-6	5.3	20
124	New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. <i>Journal of Immunology</i> , <b>2006</b> , 177, 1670-8	5.3	149
123	The human T cell response to melanoma antigens. <i>Advances in Immunology</i> , <b>2006</b> , 92, 187-224	5.6	49
122	Distinct mechanisms control human naive and antigen-experienced CD8+ T lymphocyte proliferation. <i>Journal of Immunology</i> , <b>2006</b> , 176, 2173-82	5.3	14
121	Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles. <i>Immunology and Cell Biology</i> , <b>2006</b> , 84, 318-30	5	30
120	Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. <i>Immunologic Research</i> , <b>2006</b> , 34, 67-87	4.3	39
119	Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. <i>Immunity</i> , <b>2005</b> , 22, 117-29	32.3	126
118	Methods for the ex vivo characterization of human CD8+ T subsets based on gene expression and replicative history analysis. <i>Methods in Molecular Medicine</i> , <b>2005</b> , 109, 265-84		15
117	Melanoma immunotherapy: past, present, and future. <i>Current Pharmaceutical Design</i> , <b>2005</b> , 11, 3461-73	3.3	18
116	Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. <i>Clinical and Experimental Immunology</i> , <b>2005</b> , 142, 292-302	6.2	29
115	High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. <i>European Journal of Immunology</i> , <b>2005</b> , 35, 2876-85	6.1	26
114	On the significance of CD8 alpha alpha expression for T cell memory. <i>European Journal of Immunology</i> , <b>2005</b> , 35, 3092-4	6.1	4

113	Recent advances in tumour antigen-specific therapy: in vivo veritas. <i>International Journal of Cancer</i> , <b>2005</b> , 113, 173-8	7.5	15
112	Tumor cell recognition efficiency by T cells. <i>PLoS Medicine</i> , <b>2005</b> , 2, e77; author reply e95	11.6	1
111	Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. <i>Journal of Immunology</i> , <b>2005</b> , 174, 1709-16	5.3	80
110	Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 739-46	15.9	497
109	Toward improved immunocompetence of adoptively transferred CD8+ T cells. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 1467-9	15.9	26
108	Tinkering with nature: the tale of optimizing peptide based cancer vaccines. <i>Cancer Treatment and Research</i> , <b>2005</b> , 123, 267-91	3.5	5
107	Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. <i>Cancer Research</i> , <b>2004</b> , 64, 2865-73	10.1	319
106	Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues. <i>Journal of Immunology</i> , <b>2004</b> , 172, 2773-7	5.3	16
105	Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. <i>Cancer Research</i> , <b>2004</b> , 64, 2192-8	10.1	85
104	Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells. <i>Journal of Immunology</i> , <b>2004</b> , 173, 6033-40	5.3	20
103	High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. <i>Cancer Research</i> , <b>2004</b> , 64, 6319-26	10.1	55
102	gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 668-80	12.9	68
101	Reduced L-selectin (CD62L) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. <i>Cellular Immunology</i> , <b>2004</b> , 227, 93-102	4.4	9
100	Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 249-55	7.4	62
99	Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. <i>Journal of Immunotherapy</i> , <b>2004</b> , 27, 298-308	5	36
98	Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. <i>Cancer Immunity</i> , <b>2004</b> , 4, 4		35
97	Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. <i>Journal of Immunology</i> , <b>2003</b> , 170, 5103-9	5.3	68
96	Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells. <i>Blood</i> , <b>2003</b> , 102, 1241-8	2.2	19

95	Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. <i>Blood</i> , <b>2003</b> , 102, 1779-87	2.2	142
94	Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. <i>Seminars in Cancer Biology</i> , <b>2003</b> , 13, 461-72	12.7	44
93	Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1562-73	2.2	100
92	Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. <i>Journal of Immunology</i> , <b>2003</b> , 171, 1844-9	5.3	52
91	Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 669-77	12.9	30
90	Disease-driven T cell activation predicts immune responses to vaccination against melanoma. <i>Cancer Immunity</i> , <b>2003</b> , 3, 12		8
89	Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. <i>Cancer Research</i> , <b>2003</b> , 63, 5601-6	10.1	37
88	Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multi-peptide melanoma vaccine. <i>Cancer Immunity</i> , <b>2003</b> , 3, 15		28
87	In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. <i>European Journal of Immunology</i> , <b>2002</b> , 32, 731-41	6.1	88
86	Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity. <i>European Journal of Immunology</i> , <b>2002</b> , 32, 2292-9	6.1	34
85	Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. <i>European Journal of Immunology</i> , <b>2002</b> , 32, 3285-93	6.1	22
84	T Cells in Tumor Immunity <b>2002</b> , 40-55		1
83	Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen. <i>International Journal of Cancer</i> , <b>2002</b> , 99, 201-6	7.5	4
82	Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations. <i>International Journal of Cancer</i> , <b>2002</b> , 99, 82-7	7.5	13
81	Use of phycoerythrin and allophycocyanin for fluorescence resonance energy transfer analyzed by flow cytometry: advantages and limitations. <i>Cytometry</i> , <b>2002</b> , 48, 97-105		44
80	Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. <i>Immunological Reviews</i> , <b>2002</b> , 188, 81-96	11.3	132
79	Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. <i>Oncogene</i> , <b>2002</b> , 21, 5213-23	9.2	173
78	Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. <i>Journal of Immunology</i> , <b>2002</b> , 168, 1717-22	5.3	97



77	CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. <i>Journal of Immunology</i> , <b>2002</b> , 168, 1212-8	5.3	127
76	Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL. <i>Journal of Immunology</i> , <b>2002</b> , 169, 5696-707	5.3	47
75	Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. <i>Journal of Immunology</i> , <b>2002</b> , 168, 1167-71	5.3	63
74	Thymic selection generates a large T cell pool recognizing a self-peptide in humans. <i>Journal of Experimental Medicine</i> , <b>2002</b> , 195, 485-94	16.6	130
73	Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. <i>Journal of Immunology</i> , <b>2002</b> , 168, 4231-40	5.3	76
72	Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. <i>Journal of Experimental Medicine</i> , <b>2002</b> , 196, 207-16	16.6	84
71	Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. <i>Trends in Immunology</i> , <b>2002</b> , 23, 325-8	14.4	41
70	Degeneracy instead of specificity: is this a solution to cancer immunotherapy?. <i>Trends in Immunology</i> , <b>2002</b> , 23, 344	14.4	1
69	Therapeutic cancer vaccines based on molecularly defined human tumor antigens. <i>Vaccine</i> , <b>2002</b> , 20 Suppl 4, A2-7	4.1	7
68	Modulation of proteasomal activity in vitro induces the generation of an HLA-A*0201 specific CTL-defined epitope derived from the melanoma-associated antigen MAGE-3 <b>2002</b> , 693-694		
67	Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. <i>Cancer Research</i> , <b>2002</b> , 62, 1743-50	10.1	67
66	Toward synthetic combinatorial peptide libraries in positional scanning format (PS-SCL)-based identification of CD8+ Tumor-reactive T-Cell Ligands: a comparative analysis of PS-SCL recognition by a single tumor-reactive CD8+ cytolytic T-lymphocyte clone. <i>Cancer Research</i> , <b>2002</b> , 62, 2058-63	10.1	18
65	Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?. <i>Cancer Immunity</i> , <b>2002</b> , 2, 14		10
64	Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. <i>International Journal of Cancer</i> , <b>2001</b> , 95, 73-7	7.5	31
63	Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. <i>European Journal of Immunology</i> , <b>2001</b> , 31, 459-66	6.1	40
62	Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. <i>European Journal of Immunology</i> , <b>2001</b> , 31, 2642-51	6.1	71
61	Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. <i>Journal of Immunology</i> , <b>2001</b> , 166, 7634-40	5.3	127
60	Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. <i>Journal of Immunology</i> , <b>2001</b> , 167, 3276-84	5.3	73



59	The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. <i>Journal of Immunology</i> , <b>2001</b> , 167, 6165-70	5.3	74
58	Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. <i>Journal of Immunology</i> , <b>2001</b> , 166, 4612-9	5.3	45
57	A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. <i>Journal of Immunology</i> , <b>2001</b> , 167, 5852-61	5.3	37
56	Subcellular localization of the melanoma-associated protein Melan-AMART-1 influences the processing of its HLA-A2-restricted epitope. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 43189-96	5.4	21
55	Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. <i>International Immunopharmacology</i> , <b>2001</b> , 1, 1235-47	5.8	39
54	Lack of tumor recognition by hTERT peptide 540B48-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing <b>2001</b> , 31, 2642		1
53	Generation and characterization of malaria-specific human CD8(+) lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentation by liver cells. <i>European Journal of Immunology</i> , <b>2000</b> , 30, 3079-88	6.1	35
52	Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. <i>European Journal of Immunology</i> , <b>2000</b> , 30, 3165-70	6.1	23
51	HLA-A*0201 restricted CD8+ T-lymphocyte responses to malaria: identification of new Plasmodium falciparum epitopes by IFN-gamma ELISPOT. <i>Parasite Immunology</i> , <b>2000</b> , 22, 501-14	2.2	35
50	OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. <i>Nature Immunology</i> , <b>2000</b> , 1, 502-9	19.1	187
49	Quantitation of antigen-reactive T cells in peripheral blood by IFN-gamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. <i>Journal of Immunological Methods</i> , <b>2000</b> , 244, 81-9	2.5	126
48	Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. <i>Journal of Immunological Methods</i> , <b>2000</b> , 237, 159-73	2.5	41
47	Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. <i>Journal of Immunology</i> , <b>2000</b> , 164, 1148-52	5.3	220
46	Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. <i>Journal of Immunology</i> , <b>2000</b> , 165, 533-8	5.3	77
45	Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. <i>Journal of Immunology</i> , <b>2000</b> , 165, 7253-61	5.3	73
44	Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. <i>Journal of Immunology</i> , <b>2000</b> , 164, 1125-31	5.3	70
43	Amino Acid Identity and/or Position Determines the Proteasomal Cleavage of the HLA-A*0201-restricted Peptide Tumor Antigen MAGE-3271079. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 26892-26897	5.4	13
42	In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. <i>Journal of Experimental Medicine</i> , <b>1999</b> , 190, 775-82	16.6	166

41	Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. <i>International Immunology</i> , <b>1999</b> , 11, 1971-80	4.9	44
40	High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. <i>Journal of Experimental Medicine</i> , <b>1999</b> , 190, 705-15	16.6	402
39	Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. <i>Journal of Experimental Medicine</i> , <b>1999</b> , 189, 895-906	16.6	109
38	BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. <i>Journal of Experimental Medicine</i> , <b>1999</b> , 189, 1747-56	16.6	1089
37	Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus. <i>Tissue Antigens</i> , <b>1999</b> , 53, 519-26		4
36	Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1999</b> , 45, 735-41	4	22
35	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. <i>European Journal of Immunology</i> , <b>1999</b> , 29, 1990-9	6.1	102
34	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients <b>1999</b> , 29, 1990		1
33	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients <b>1999</b> , 29, 1990		7
32	Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. <i>Trends in Molecular Medicine</i> , <b>1998</b> , 4, 305-12		68
31	Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. <i>International Journal of Cancer</i> , <b>1998</b> , 78, 699-706	7.5	62
30	Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 188, 1641-50	16.6	443
29	High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 188, 1203-8	16.6	360
28	Circulating MELAN-A/MART-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype <b>1998</b> , 78, 699		1
27	Differential roles of T cell receptor alpha and beta chains in ligand binding among H-2Kd-restricted cytolytic T lymphocyte clones specific for a photoreactive Plasmodium berghei circumsporozoite peptide derivative. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 8505-14	5.4	16
26	Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen. <i>International Journal of Cancer</i> , <b>1997</b> , 72, 1045-55	7.5	9
25	N-acetyl-L-cysteine Exhibits Antitumoral Activity by Increasing Tumor Necrosis Factor $\alpha$ -Dependent T-Cell Cytotoxicity. <i>Blood</i> , <b>1997</b> , 90, 1124-1132	2.2	1
24	HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 12463-71	5.4	21

23	Recognition of tumor-associated antigens by T-lymphocytes: perspectives for peptide-based vaccines. <i>Annals of Oncology</i> , <b>1996</b> , 7, 339-42	10.3	1
22	A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. <i>Immunogenetics</i> , <b>1996</b> , 43, 377-83	3.2	90
21	Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. <i>International Journal of Cancer</i> , <b>1996</b> , 66, 162-9	7.5	163
20	Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. <i>Seminars in Immunopathology</i> , <b>1996</b> , 18, 185-98		10
19	The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. <i>Journal of Investigative Dermatology</i> , <b>1996</b> , 107, 63-7	4.3	51
18	CD8 beta increases CD8 coreceptor function and participation in TCR-ligand binding. <i>Journal of Experimental Medicine</i> , <b>1996</b> , 184, 2439-44	16.6	73
17	CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. <i>Nature</i> , <b>1995</b> , 373, 353-6	50.4	202
16	CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. <i>Immunology Letters</i> , <b>1995</b> , 46, 199-205	4.1	31
15	Structural analysis of TCR-ligand interactions studied on H-2Kd-restricted cloned CTL specific for a photoreactive peptide derivative. <i>Immunity</i> , <b>1995</b> , 3, 51-63	32.3	48
14	Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone. <i>European Journal of Immunology</i> , <b>1994</b> , 24, 1458-62	6.1	39
13	Leishmania major infection in mice primes for specific major histocompatibility complex class I-restricted CD8+ cytotoxic T cell responses. <i>European Journal of Immunology</i> , <b>1994</b> , 24, 2813-7	6.1	51
12	Efficient in vivo induction of CTL by cell-associated covalent H-2Kd-peptide complexes. <i>Journal of Immunological Methods</i> , <b>1994</b> , 171, 73-84	2.5	9
11	MHC class I H-2Kd-restricted antigenic peptides: additional constraints for the binding motif. <i>International Immunology</i> , <b>1993</b> , 5, 1489-92	4.9	19
10	Differential T cell receptor photoaffinity labeling among H-2Kd restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. Labeling of the alpha-chain correlates with J alpha segment usage. <i>Journal of Experimental Medicine</i> , <b>1993</b> , 177, 1247-56	16.6	23
9	The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. <i>International Journal of Cancer</i> , <b>1993</b> , 54, 527-8	7.5	72
8	T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. <i>Journal of Immunological Methods</i> , <b>1992</b> , 155, 95-9	2.5	82
7	Specific binding of antigenic peptides to cell-associated MHC class I molecules. <i>Nature</i> , <b>1991</b> , 351, 72-4	50.4	44
6	CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. <i>International Immunology</i> , <b>1991</b> , 3, 579-85	4.9	194

5	The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides. <i>International Immunology</i> , <b>1991</b> , 3, 1035-42	4.9	34
4	Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. <i>Immunology Letters</i> , <b>1990</b> , 25, 27-31	4.1	32
3	Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. <i>Nature</i> , <b>1989</b> , 341, 323-6	50.4	433
2	A synthetic vaccine protects humans against challenge with asexual blood stages of <i>Plasmodium falciparum</i> malaria. <i>Nature</i> , <b>1988</b> , 332, 158-61	50.4	348
1	Induction of protective immunity against experimental infection with malaria using synthetic peptides. <i>Nature</i> , <b>1987</b> , 328, 629-32	50.4	254